YANG Bo has been committed to the discovery and innovation of new targets of anti-tumor drugs for many years, and has successively discovered a series of new targets and candidate drugs such as CDK2 and WSB1.

During 2020, her team uncovered the key reasons of skin toxicity of Sorafenib, an anti-tumor drug, and proposed a toxic intervention strategy utilizing SIRT1 inhibitor for Sorafenib hand foot syndrome. The research achievements were published in Cell Research and is currently in the process of phase II clinical trials. In addition, focusing on the clinical problems of poor selectivity of Akt inhibitors subtypes, Yang’s team developed the New Molecular Entity Hu7691 with independent intellectual property rights, working together with the pharmaceutical team. Hu7691 was licensed for clinical trials by the State Drug Administration.

 Hangzhou Institute of Innovative Medicine, Zhejiang University and Intelligent Innovation Drug Research Institute,  Zhejiang University, which were set up under her lead, respectively put into operation and made important progress, playing an important role in the high-speed and high-quality development of Pharmacy in Zhejiang University, and providing an important platform for young teachers’ development.